Elutia Inc. (ELUT) stock

ELUTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 8/3022% below fair value

$0.82−0.06 (-6.69%)

Close on Nov 13, 2026Market cap $36.32MP/E –Yield –

Elutia operating margin

Operating margin is operating income as a percentage of revenue.

Elutia's operating margin for the twelve months ending Sep 30, 2026 was -152.3%. For fiscal 2025 it was -218.9%, against -212.3% the year before. The highest annual figure on record is -19.6% in fiscal 2019.

Annual operating margin

Period	Period end	Value	Change (pts)
FY2025	Dec 31, 2025	-218.9%	−6.6
FY2024	Dec 31, 2024	-212.3%	−88.9
FY2023	Dec 31, 2023	-123.4%	+24.2
FY2022	Dec 31, 2022	-147.5%	−98.9
FY2021	Dec 31, 2021	-48.6%	−16.7
FY2020	Dec 31, 2020	-31.9%	−12.3
FY2019	Dec 31, 2019	-19.6%	–

Quarterly operating margin

Change is against the same quarter a year earlier.

Period	Period end	Value	Change (pts)
Q3 FY2026	Sep 30, 2026	-606.5%	+15.2
Q2 FY2026	Jun 30, 2026	-327.9%	−23.3
Q1 FY2026	Mar 31, 2026	-203.9%	+25.8
Q4 FY2025	Dec 31, 2025	-45.1%	+219.8
Q3 FY2025	Sep 30, 2025	-621.7%	−371.2
Q2 FY2025	Jun 30, 2025	-304.5%	−169.2
Q1 FY2025	Mar 31, 2025	-229.7%	−103.0
Q4 FY2024	Dec 31, 2024	-264.8%	−120.0
Q3 FY2024	Sep 30, 2024	-250.5%	−130.2
Q2 FY2024	Jun 30, 2024	-135.3%	−35.9
Q1 FY2024	Mar 31, 2024	-126.7%	+3.8
Q4 FY2023	Dec 31, 2023	-144.8%	−80.1
Q3 FY2023	Sep 30, 2023	-120.3%	−60.1
Q2 FY2023	Jun 30, 2023	-99.3%	−27.9
Q1 FY2023	Mar 31, 2023	-130.5%	−69.7
Q2 FY2022	Jun 30, 2022	-64.7%	−27.0
Q1 FY2022	Mar 31, 2022	-60.2%	−31.5
Q4 FY2021	Dec 31, 2021	-71.5%	−39.7
Q3 FY2021	Sep 30, 2021	-60.7%	−37.9
Q2 FY2021	Jun 30, 2021	-37.8%	+6.1
Q1 FY2021	Mar 31, 2021	-28.7%	+3.6
Q4 FY2020	Dec 31, 2020	-31.8%	−5.2
Q3 FY2020	Sep 30, 2020	-22.9%	−6.3
Q2 FY2020	Jun 30, 2020	-43.9%	–
Q1 FY2020	Mar 31, 2020	-32.3%	–
Q4 FY2019	Dec 31, 2019	-26.6%	–
Q3 FY2019	Sep 30, 2019	-16.6%	–